Form 8-K - Current report:
SEC Accession No. 0000950170-24-110066
Filing Date
2024-09-27
Accepted
2024-09-27 16:55:17
Documents
14
Period of Report
2024-09-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-20240927.htm   iXBRL 8-K 58823
2 EX-1.1 achv-ex1_1.htm EX-1.1 327382
3 EX-5.1 achv-ex5_1.htm EX-5.1 27070
4 GRAPHIC img223336490_0.jpg GRAPHIC 19105
  Complete submission text file 0000950170-24-110066.txt   658107

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20240927.xsd EX-101.SCH 51386
17 EXTRACTED XBRL INSTANCE DOCUMENT achv-20240927_htm.xml XML 6342
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 241335722
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)